March 2026: Biotech & Pharma NEWS Roundup

Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026!

This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, and a storyteller by choice. 

Due to continued demand, I’m reporting monthly episodes for biotech and pharma news. Each monthly recap for news is released on the first day of every month and my goal is to deliver digestible pieces of news on pharma and biotech companies in under 15 mins.

Grab your coffee or tea cuz you’re in for a treat! 

The AI & Computational Frontier

• Roche & Nvidia AI Chip Acquisition (https://www.roche.com/media/releases/med-cor-2026-03-16): In a massive infrastructure play, Roche has purchased thousands of Nvidia H200 AI chips to accelerate its drug discovery and development timelines. The goal is to move away from traditional "wet lab" trial-and-error by using massive compute power to simulate protein folding and molecular interactions. By internalizing this hardware, Roche aims to build the industry's most powerful "Generative Biology" cluster, potentially cutting years off the pre-clinical phase.
• Insilico Medicine & Eli Lilly ($2.75B) (https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-sign-2-billion-deal-ai-drug-development-with-hong-kongs-insilico-2026-03-29/): Eli Lilly has solidified its lead in AI-driven R&D by securing a massive $2.75 billion drug discovery collaboration with Insilico Medicine. The partnership will utilize Insilico’s "Pharma.AI" platform to hunt for novel targets across Lilly's core pillars of metabolic disease and oncology. This "biobucks" pact is one of the largest to date, signaling that Lilly is moving AI from a "side project" to the center of its primary pipeline.
• Merck & Infinimmune ($838M) (https://www.fiercebiotech.com/biotech/merck-enlists-antibody-hunter-infinimmune-838m-biobucks): Merck has enlisted the "antibody hunter" Infinimmune in an $838 million biobucks pact focused on discovering ultra-rare, high-affinity antibodies. The goal is to leverage Infinimmune’s platform to identify human antibodies from "elite responders" in the immune system to target complex cancers. This deal represents Merck’s continued aggressive expansion into next-generation immunotherapy ahead of the Keytruda patent cliff.

The GLP-1 & Metabolic Super-Cycle

• Eli Lilly’s Compounding Warnings (https://endpoints.news/lilly-warns-of-impurity-risk-in-certain-compounded-forms-of-mounjaro-and-zepbound/): As the supply crunch for weight-loss drugs continues, Eli Lilly issued a high-profile warning regarding "impurity risks" found in certain compounded forms of Mounjaro and Zepbound. The company cited findings of bacteria and incorrect dosage levels in unregulated "gray market" versions, aiming to steer patients back to official, FDA-approved pens. This is a critical legal and PR move to protect their "Metabolic Franchise" during a period of peak global demand.
• Lilly’s China Expansion & South Korea Pledge ($500M) (https://endpoints.news/lilly-plots-glp-1-pill-production-boost-in-china-500m-pledge-to-south-korea/): Recognizing that the fight for GLP-1 dominance is a global supply chain battle, Eli Lilly is plotting a major production boost for its "pill-form" tirzepatide in China. Simultaneously, the firm pledged $500 million to South Korea to bolster clinical research and high-tech manufacturing resilience. These moves aim to establish a "Metabolic Moat" in Asia and diversify their production footprint away from purely Western sites.
• The Hims vs. Novo Nordisk Feud (https://endpoints.news/watch-who-won-the-hims-vs-novo-feud/): The pharmaceutical world is watching the fallout of the feud between telehealth disruptor Hims & Hers and the Danish giant Novo Nordisk. Hims has built a massive business selling compounded semaglutide during national shortages, a move Novo is now challenging through intense lobbying and potential legal action. The outcome will determine if "telehealth-first" companies can continue to capitalize on Big Pharma's supply chain vulnerabilities.

High-Stakes M&A & Takeover Bids

• Eli Lilly Buys Centessa Pharmaceuticals ($6.3B) (https://www.wsj.com/health/pharma/eli-lilly-to-buy-centessa-pharmaceuticals-for-initial-6-3-billion-bfedfc34?gaa_at=eafs&gaa_n=AWEtsqd32qoyEPv1f-a3sL8ogN4G_6lUvFCl-wN31L4QaYoQPpsPJeUsw2HxGQKkq-0%3D&gaa_ts=69cbe923&gaa_sig=xEoVxBqwuYnQpr2zZa1ve3wJNmn39cHq0hYfpKU_O9P3loiwveE7MEdXcqw1GTmnbEMjN9D_XLYojolzfnHu_g%3D%3D): In a staggering move to dominate the rare disease and hematology space, Eli Lilly has agreed to acquire Centessa Pharmaceuticals for an initial $6.3 billion. The deal centers on Centessa's promising "Hemophilia B" and "Orexin" programs, which fit perfectly into Lilly’s broader strategy of diversification. This acquisition adds a layer of high-science depth to Lilly's already dominant commercial portfolio.
• Merck Buys Terns Pharmaceuticals ($6.7B) (https://www.cnbc.com/amp/2026/03/25/merck-buy-terns-pharmaceuticals-mrk-stock-boost-cancer-pipeline.html): Merck has made its largest move of the year by acquiring Terns Pharmaceuticals for $6.7 billion to bolster its oncology and NASH (liver disease) pipelines. The deal gives Merck access to Terns' allosteric BCR-ABL inhibitors, which are seen as a vital defensive asset as the Keytruda patent expiry nears. This purchase signals Merck’s intent to maintain its oncology crown through aggressive, high-value "bolt-on" acquisitions.
• Biogen Acquires Apellis (https://www.stocktitan.net/news/BIIB/biogen-to-acquire-apellis-enhancing-the-company-s-growth-portfolio-q1rcicath0hx.html): In a strategic pivot toward immunology and rare disease, Biogen has moved to acquire Apellis Pharmaceuticals. The goal is to accelerate Biogen's expansion into Nephrology and geographic atrophy, leveraging Apellis’s C3 therapy platform to offset stagnation in the MS market. This deal is expected to significantly bolster Biogen's growth outlook and provide a much-needed second act in high-margin specialty medicine.
• Gilead Buys Ouro Medicines ($2B+) (https://sg.finance.yahoo.com/news/gilead-buy-biotech-firm-ouro-223057847.html): Gilead Sciences is using its HIV-generated cash reserves to buy into the metabolic boom, acquiring Ouro Medicines in a deal valued at over $2 billion. Ouro specializes in "next-gen" metabolic candidates that could act as "add-on" therapies for obesity and inflammatory conditions. This move reflects Gilead’s broader strategy of reducing its dependence on virology and establishing a foothold in the cardiometabolic space.
• Servier Buys Day One ($2.5B) (https://endpoints.news/servier-to-buy-day-one-for-2-5b-gaining-rare-oncology-medicines/): Continuing its transformation into an oncology powerhouse, Servier has agreed to acquire Day One Biopharmaceuticals for $2.5 billion. The deal is built around Ojemda (tovorifenib), a rare pediatric medicine for low-grade gliomas. This acquisition solidifies Servier’s position as a global leader in treating rare, life-altering cancers, particularly in the pediatric space.
• Recordati’s $12B+ Takeover Bid (https://endpoints.news/recordati-says-its-received-a-12b-takeover-bid/): The Italian pharmaceutical firm Recordati announced it has received a massive takeover bid exceeding $12 billion from an undisclosed suitor. The goal of the potential buyer is likely to secure Recordati’s lucrative rare disease portfolio and established European commercial footprint. If completed, this would be one of the largest "private equity to strategic" exits in the European pharma sector this decade.
• Novartis & Synnovation ($2B Upfront) (https://endpoints.news/novartis-to-pay-2b-upfront-to-take-next-gen-pi3k%CE%B1-inhibitor-from-synnovation/): Novartis has struck a blockbuster deal to acquire Pikavation Therapeutics (a subsidiary of Synnovation) for $2 billion upfront and up to $1 billion in milestones. The goal is to secure SNV4818, a next-generation "pan-mutant selective" PI3Kα inhibitor designed to treat HR+/HER2- breast cancer while sparing healthy cells. This selectivity aims to eliminate the severe hyperglycemia seen with older drugs like Piqray, allowing Novartis to finally unlock the "holy grail" of triple-combination therapies.

Strategic Licensing & Divestitures

• Lonza Sells Capsule Unit ($2.2B) (https://endpoints.news/lonza-sells-capsule-and-health-ingredients-unit-for-2-2b/): In a major streamlining effort, Lonza has sold its capsule and health ingredients unit to the UK-based private equity firm Lone Star for $2.2 billion upfront. The goal is to shed its more "commodity-like" manufacturing business to focus entirely on its high-margin CDMO (Contract Development and Manufacturing) services for biologics and cell therapies. This divestiture provides Lonza with a massive cash injection to expand its high-tech bioreactor capacity.
• GSK Licenses Liver Pill to Alfasigma ($300M) (https://endpoints.news/gsk-licenses-linerixibat-for-liver-disease-itch-to-alfasigma-for-300m-upfront/): GSK has licensed its oral treatment for liver disease-related itching to the Italian firm Alfasigma for $300 million upfront. The goal is to allow Alfasigma to handle the specialized commercialization of this niche product while GSK focuses its internal resources on its massive vaccines and HIV portfolios. This deal represents a classic "portfolio pruning" move, ensuring the drug reaches patients through a more focused partner.
• UCB & Antengene T-Cell Deal ($60M) (https://endpoints.news/ucb-boards-t-cell-engager-train-in-60m-upfront-deal-with-antengene/): UCB has officially boarded the "T-cell engager train" by securing a licensing deal with Antengene for $60 million upfront. The partnership focuses on a multi-specific T-cell engager designed to treat hematologic malignancies and potentially autoimmune conditions. This relatively small upfront payment hides a massive potential for "biobucks" if the technology proves more effective than current CAR-T therapies.

Neuroscience & Psychiatric Breakthroughs

• Otsuka Buys Transcend ($1.2B) (https://www.fiercebiotech.com/biotech/otsuka-picks-transcend-1225b-acquisition-highlighting-mdma-analog): Otsuka has acquired Transcend Therapeutics for $1.2 billion, gaining access to a highly anticipated MDMA analog for psychiatric conditions. Unlike traditional MDMA, this analog is designed for a shorter duration and lower cardiovascular strain, making it a "best-in-class" candidate for clinic-based PTSD therapy. This deal positions Otsuka as the leading Big Pharma player in the "Psychedelic Medicine" space.
• Shionogi & Apnimed JV ($100M) (https://www.fiercebiotech.com/biotech/shionogi-pays-apnimed-100m-joint-venture-awaken-sleep-disorder-dream): Shionogi has paid Apnimed $100 million to form a joint venture aimed at commercializing a "pill-based" treatment for obstructive sleep apnea. The goal is to disrupt the multi-billion dollar CPAP device market by providing a pharmacological alternative for millions of patients who struggle with masks. This partnership represents a major bet on a "lifestyle-improving" drug for a historically difficult-to-treat respiratory condition.

Global Policy & Financial Markets

• China is going after the most expensive drugs (https://endpoints.news/china-is-going-after-the-worlds-most-expensive-drugs-endpoints-signal/): China is reportedly launching an aggressive regulatory crackdown on "the world's most expensive drugs," according to recent Endpoints Signal reports. The goal is to force massive price cuts on imported biologics and orphan drugs in exchange for inclusion on the National Reimbursement Drug List (NRDL). This move has sent shockwaves through Big Pharma, as China remains a critical growth engine for their high-priced specialty medicines.
• Blackstone’s $6.3B Life Sciences Fund (https://endpoints.news/blackstone-to-support-teva-on-sanofi-partnered-tl1a-with-400m/, https://www.blackstone.com/news/press/blackstone-announces-final-close-of-record-6-3-billion-life-sciences-fund-the-largest-private-fund-dedicated-to-life-sciences/): Private equity titan Blackstone announced the final close of its record-breaking $6.3 billion Life Sciences Fund (BXLS V). This "war chest" is designed to provide late-stage funding and royalty deals for biotech companies facing a difficult IPO market. Their first major move—a $400 million support package for Teva and Sanofi’s TL1A program—shows Blackstone is now acting as a critical "private bank" for the industry's most expensive clinical trials.
• Universal Health Services Buys Talkspace ($835M) (https://endpoints.news/universal-health-services-buys-talkspace-for-835m/): In a major move for integrated behavioral health, UHS has acquired digital therapy leader Talkspace for $835 million. The goal is to blend UHS’s physical psychiatric hospitals with Talkspace’s digital reach to create a "full-spectrum" mental health provider. This deal marks the first major instance of a legacy hospital chain buying a digital health startup to manage patient care outside the clinic walls.

Executive & Corporate Shifts

• The BioNTech Founders’ New Venture (https://www.biospace.com/business/biontech-founders-to-leave-famed-mrna-biotech-for-new-venture): In a stunning shift, the founders of BioNTech (Ugur Sahin and Özlem Türeci) have announced they are stepping back from daily roles to launch a "new venture." While they remain major shareholders, their new startup will reportedly focus on "Programmable Immunology," moving beyond mRNA to create intelligent cells that hunt specific cancers. This marks the transition of BioNTech into a mature, corporate-led vaccine giant.
• Bavarian Nordic CEO Exit (https://endpoints.news/bavarian-nordic-ceo-paul-chaplin-exits-months-after-failed-3b-takeover/): Paul Chaplin has exited as CEO of Bavarian Nordic, just months after the company's ambitious $3 billion takeover of travel vaccines from Emergent BioSolutions failed to stabilize the stock. The board is now seeking a leader who can navigate the post-pandemic vaccine landscape. Chaplin’s departure highlights the immense pressure on mid-sized vaccine firms to find growth in an increasingly crowded market.

With that, that is a wrap for March 2026 news.

This has been Petri Dish Perspectives. I’m Manead. I’ll be back next month with a recap on April. Thanks for listening. Goodbye!